Skip to content

Kura Oncology KURA Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
-$13.92M-191%
Nuvation Bio logo
Nuvation BioNUVB
$3.91M+107%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$50.67M-3.9%
Nuvalent, Inc. logo
Nuvalent, Inc.NUVL
-$112.99M-35.0%
Tyra Biosciences, Inc. logo
Tyra Biosciences, Inc.TYRA
-$39.59M-40.2%
Bicara Therapeutics logo
Bicara TherapeuticsBCAX
-$56.7M-53.9%

Other financials

Income statement

See full
Revenue$18.3M+29.5%
Gross profit$18.0M
Operating income-$78.8M-21.8%
Net income-$73.3M-27.7%
EPS (diluted)-$0.83-25.8%

Balance sheet

See full
Cash & equivalents$39.1M-23.8%
Total debt$24.3M+25.4%
Total equity$107.9M-70.4%
Total assets$652.6M-12.3%

Cash flow

See full
Operating cash flow-$85.9M-19.4%
CapEx$128.0K-56.2%
Free cash flow-$86.0M-19.1%

Valuation

See full
Market cap$919.7M+81.6%
Enterprise value$904.89M+90.7%
P/S12.8×+3.5×

Profitability

See full
Operating margin-443.5%+103pp
Net margin-411.2%+125pp
FCF margin130.6%+74.1pp

Returns & leverage

See full
Return on equity-124.7%-252pp
Debt / equity0.2×+0.2×
Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kura Oncology's comprehensive income (loss), net of tax, attributable to parent?
Kura Oncology (KURA) reported comprehensive income (loss), net of tax, attributable to parent of -$74.74M in Q1 2026.
How has Kura Oncology's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Kura Oncology's comprehensive income (loss), net of tax, attributable to parent decreased by 30.6% year-over-year, from -$57.22M to -$74.74M.
What is the long-term trend for Kura Oncology's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Kura Oncology's comprehensive income (loss), net of tax, attributable to parent has grown at a 20.4% compound annual growth rate (CAGR), from -$132.3M to -$278.41M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from non-owner sources, including net income and other comprehensive income items such as unrealized gains or losses on securities. It provides a broader view of the company's financial performance beyond traditional net income by incorporating market-related adjustments. This figure is essential for assessing the total impact of economic events on the company's comprehensive financial health.